Monoclonal antibodies and vaccine development directed to human

Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

4241841, 4241931, 514 8, 514 23, 530395, A61K 3814, A61K 3900, A61K 3939, C07K 1482

Patent

active

057470480

ABSTRACT:
A method of producing monoclonal antibodies that bind to human cancer-associated mucin-type glycoprotein antigens comprising: (1) immunizing a host with a core structure of a mucin-type glycoprotein; (2) fusing splenocytes from said immunized host with myeloma cells to form hybridoma cells; (3) culturing said hybridoma cells on selective medium; (4) selecting hybridoma cells surviving step (3) that secrete antibody that binds to said core structure of a mucin-type glycoprotein; (5) cloning said selected hybridoma cells from step (4); (6) culturing said cloned hybridoma cells; and (7) recovering said antibody. Hybridomas and monoclonal antibodies produced by the above-described method. Methods of passive and active immunization employing the monoclonal antibodies and mucin-type glycoproteins or synthetic oligosaccharide-carrier conjugates.

REFERENCES:
patent: 4444744 (1984-04-01), Goldenberg
Kurosaka et al., JBC 263, 8724 (1988).
Kurosawa A., et al., FEBS Lett 215:137-139, 1987.
Hakomori et al., J. Biol. Chem. 258:11819-11822.
Ross et al., Journal of the National Cancer Institute, vol. 73, p. 731 (1984).
Nuti M, et al., Intl. J. Cancer 29:539-545, 1982.
Johnson VG, et al., Cancer Res. 46:850-857, 1986.
Thor A, et al., Cancer Res. 46:3118-3124, 1986.
Feizi, T., et al; Biochem. Soc. Trans. 12(4):591-6 (1984), "Mucin-type glycoproteins".
Hakomori, S., et al. Cancer Res. 45(6):2405-14 (1985) "Aberrant Glycosylation in Cancer Cell Membranes as Focused on Glycolipids: Overview and Perspectives".
Houghton, A.N. et al. PNAS USA 82:1242-46 (1985) "Mouse Monoclonal IgG3 Antibody Detecting GD3 Ganglioside: A Phase I Trial in Patients with Malignant Melanoma".
Schreiber, H. In Fundamental Immunology, W. F. Paul editor (1989). "Tumor Immunology" pp. 923-955.
Sundsmo, J.S. et al. Biochem. Biophys. Res. Comm, 68(3):799-806 (1976), "Lacto-N-Neotetrasylceramide (Paragloboside) as a Possible Tumor-Associated Surface Antigen . . . ".
Gupta, R. K. et al. Vaccine 11(3):293-306 (1993) "Adjuvants--a Balance Between Toxicity and Adjuvanicity".
Rabinovich, N. B. et al. Science 265:1401-4 (2 Sep. 1994), "Vaccine Technologies: View to the Future".
Dermer, G. B. Bio/Technology 12:320(Mar. 1994), "Another Anniverrsay of the War on Cancer".
Osband, M. E. et al., Immunol. Today 11(6):193-195 (1990), "Problems in the Investigational Study and Clinical Use of Cancer Immunotherapy".
Springer, Georg F., Science 224:1198-1206, "T and Tn, General Carcinoma Autoantigens", Jun. 1984.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Monoclonal antibodies and vaccine development directed to human does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Monoclonal antibodies and vaccine development directed to human , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies and vaccine development directed to human will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-51191

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.